Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT03425006
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Itacitinib — DRUG
    a JAK 1 selective small molecule inhibitor
  • Pembrolizumab — BIOLOGICAL
    a highly selective humanized monoclonal antibody (mAb)

Study Details

This is a single center, single arm phase 2 study to establish the safety and efficacy of itacitinib (also known as INCB039110) administered in combination with pembrolizumab in patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC).

Key Dates

Start date
Jun 18, 2018
Status verified
Aug 2023
Primary completion
Jun 17, 2021
Completion
Oct 11, 2021

Study Design

Enrollment
23 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Itacitinib and Pembrolizumab

Primary Outcome Measure

Number of Subjects With a Response at 12 Weeks According to RECIST 1.1 for the Combination of Pembrolizumab and Itacitinib Among Patients With Previously Untreated, PD-L1 Positive Metastatic NSCLC. [ Time Frame: 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of PennsylvaniaPhiladelphiaPennsylvania19104-

Find similar trials in Philadelphia, PA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of Pennsylvania· Philadelphia, PA

Related Studies